Truist Securities analyst Danielle Brill assumes coverage on Rapport Therapeutics (NASDAQ: RAPP) with a Buy rating and a price target ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage